ROSS SPAC will issue $280 million of stock for APRINOIA Therapeutics
Precision Neurology Company Focused on Developing a Pipeline of Highly Specific Central Nervous System (“CNS”) Diagnostics and Therapeutics, including CNS Protein Degraders
Anticipated Proceeds From Transaction Expected to Finance Several Key Therapeutic and Diagnostic Programs to Data Announcements
Business Combination is Expected to be Completed in 1H 2023 and the Combined Company is Expected to be traded on Nasdaq or NYSE upon Closing
Palm Beach, FL and CAMBRIDGE, MA, January 18, 2023 – APRINOIA Therapeutics Inc. (“APRINOIA”), a clinical-stage biotechnology company focused on neurodegenerative diseases such as Alzheimer’s Disease (“AD”) and Progressive Supranuclear Palsy (“PSP”), and Ross Acquisition Corp II (NYSE: ROSS, ROSS.U, ROSS WS) (“ROSS”), a special purpose acquisition company founded by former Commerce Secretary Wilbur Ross, today announced that they have entered into a definitive agreement (the “Business Combination Agreement”) for a business combination (the “Business Combination”).
ROSS and APRINOIA are combining at an implied fully diluted transaction equity value of US$280 million for APRINOIA. As part of the Business Combination, Mr. Ross has personally invested US$7.5 million through a convertible note and has committed to provide up to US$12.5 million of capital infusion at the closing of the Business Combination (the “Closing”). This funding is intended to meet the capital requirements needed to bring the company’s lead product, 18F-APN-1607 (“APN-1607”), through to commercialization in China.
APRINOIA, incorporated in 2015, is a Cambridge, MA based global clinical-stage biotech company developing novel therapeutics and precision diagnostics for the treatments of neurodegenerative diseases in collaboration with leading global biotech companies such as Biogen and Celgene (acquired by Bristol Myers Squibb), which includes certain non-exclusive license agreements on its lead tau PET tracer, APN-1607. Concurrently with this announcement, APRINOIA is also announcing the out license of the China rights of APN-1607 to a large pharmaceutical company, whereby such company licensee has executed a binding term sheet agreeing to lead the product through its current Phase 3 trial in AD and target 2024 for commercialization of APN-1607 in China, subject to regulatory review and approval. The licensee has committed approximately US$8 million and RMB 14 million as an upfront payment and has committed to milestone payments and royalties of up to 15% of sales in China, where it is estimated that around 10 million people suffer from AD. APRINOIA will continue to lead the development of APN-1607 in other jurisdictions. APN-1607 is in a Phase 2 trial for AD, with sites in the United States, Japan, and Taiwan, and is preparing for a Phase 3 trial in PSP in the United States, subject to regulatory approval of the FDA.
APRINOIA has established four platforms with different modalities: unique PET diagnostic tracers, small molecule modulators, antibodies, and degraders. Each of the modalities targets pathological aggregated proteins such as tau, alpha-Synuclein, and TDP43 that contribute to the pathogenesis of rare dementia or movement disorders, including PSP, multiple system atrophy (“MSA”) and frontotemporal dementia (“FTD”), as well as common diseases such as AD and Parkinson’s diseases (“PD”).
APN-1607 is a new generation tau PET tracer with a higher specificity than older generations to the pathological tau aggregates and an improved off-target profile. APN-1607 has been validated in 2,600+ human subjects, demonstrating wide clinical utilities for AD and non-AD tauopathies, including PSP, corticobasal degeneration (“CBD”) and traumatic brain injuries to differentially quantify the amount and spatial distribution of tau protein abnormality in those patients. Its features potentially enable more accurate clinical diagnosis in earlier stages, distinguish different stages of these diseases, may help monitor disease progression over time, and potentially allow clinicians to differentiate among different types of neurodegenerative diseases. APRINOIA leverages the advantage of image-validated binders to form the core of its protein degraders, with the benefit of knowing that these binders have shown statistically significant correlation to disease worsening in diseases such as AD and PSP (based on physician scoring). It is APRINOIA’s goal, whether independently or with a pharma partner, to be the first company to advance a CNS protein degradation molecule into human clinical studies.
APRINOIA is also currently running a Phase 1 study in the United States for its tau antibody, APN-005. This antibody targets a conformational-dependent epitope in the mid-domain region of tau, which epitope is thought to be exclusively present on aggregated forms of tau.
“After 7 years of dedicated R&D on neurodegeneration to realize precision neuroscience, we are excited to take our company to the next level of finance and corporate development. Our R&D and collaboration successes are a demonstration of the quality of our products, our team, and the support of our research and commercial partners. We will continue to grow our company and our pipeline to develop innovative products for our physicians and patients with critical medical needs,” said Ming-Kuei Jang, CEO of APRINOIA.
“We are excited to partner with APRINOIA and support its quest in addressing one of the most important disease areas. With more than 6.5 million Alzheimer’s patients in the US currently, and an economic burden expected to reach over US$350 billion by 2040, it became clear that this was a problem worth our attention. APRINOIA’s tau approach is potentially complementary to beta-Amyloid based products like Lecanemab. We’re encouraged by the progress made in this field over the last two years, and believe we’re partnering with APRINOIA at the right time to continue advancing this field,” added Wilbur Ross, CEO of ROSS.
“APRINOIA is an advanced biotechnology company focused on tauopathies and alpha-synucleinopathies, which are neurodegenerative diseases that continue to alarmingly increase in numbers globally,” added Nadim Qureshi, Head of M&A for ROSS.
Proposed Business Combination Overview
ROSS has entered into the Business Combination Agreement with APRINOIA, pursuant to which APRINOIA and ROSS will each become a wholly owned subsidiary of the combined company, APRINOIA Therapeutics Holdings Limited, a newly formed entity (“PubCo”). The Business Combination values the post-closing combined business at a pro forma enterprise value of up to US$319.6 million.
As part of the Business Combination, all of APRINOIA’s existing shareholders will roll 100% of their shares in APRINOIA into PubCo. APRINOIA’s existing shareholders expect to hold between 42% and 74% of PubCo depending on the level of redemptions by ROSS shareholders.
APRINOIA will receive the remaining proceeds held in ROSS’s trust account following the redemptions by ROSS shareholders, an additional US$7.5 million from an affiliate of Mr. Wilbur Ross and US$5 million in commitments from other investors, including existing shareholders of APRINOIA. There is approximately US$350.6 million currently held in ROSS’s trust account.
The boards of directors of both ROSS and APRINOIA have each unanimously approved the proposed Business Combination, which is expected to close in the first half of this year, subject to customary approvals and conditions, including the approval by ROSS’s shareholders. Upon Closing, APRINOIA’s business will operate under the APRINOIA name. Pursuant to the terms of the Business Combination Agreement, as a closing condition, PubCo is required to cause the PubCo ordinary shares issued in connection with the Business Combination to be approved for listing on NYSE or Nasdaq, but there can be no assurance that such listing condition will be met.
Investor Presentation
APRINOIA and Ross Acquisition Corp II will be hosting an investor call and slide presentation at 4:30 pm ET on Wednesday, January 18, 2023. Webcast and dial-in information can be found below:
Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=GOhNT3ve
Conference Call: 877-407-8029 or +1 201 689-8029
An investor presentation with detailed information regarding the proposed Business Combination will be filed by ROSS as an exhibit to a Current Report on Form 8-K, which can be reviewed on the website of U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.
Advisors
BTIG, LLC acted as the financial advisor to APRINOIA in connection with the proposed Business Combination. Allele Capital Partners, LLC acted as a strategic advisor to APRINOIA.
Cooley LLP acted as legal advisor to APRINOIA in connection with the proposed Business Combination.
White & Case LLP acted as legal advisor to ROSS in connection with the proposed Business Combination. Jones Day acted as legal advisor to ROSS in connection with certain securities matters.
About APRINOIA
APRINOIA Therapeutics Inc., incorporated in 2015, is a Cambridge, MA based global clinical- stage biotech company developing novel therapeutics and precision diagnostics for the treatments of neurodegenerative diseases in collaboration with leading global biotech companies.
About Ross Acquisition Corp II
Ross Acquisition Corp II is a special purpose acquisition company sponsored by Ross Holding Company LLC, an affiliate of Wilbur L. Ross, Stephen J. Toy, and Nadim Z. Qureshi, for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or assets. Ross Acquisition Corp II completed its initial public offering in March 2021, raising approximately $345 million in cash proceeds.
Additional Information and Where to Find It
This communication relates to the proposed Business Combination between ROSS and APRINOIA. In connection with the Business Combination, PubCo intends to file a registration statement on Form F-4 with the SEC, which will include a proxy statement to ROSS shareholders and a prospectus for the registration of PubCo securities to be issued in connection with the Business Combination (as amended from time to time, the “Registration Statement”). After the Registration Statement is declared effective by the SEC, the definitive proxy statement/prospectus and other relevant documents will be mailed to the shareholders of ROSS as of the record date in the future to be established for voting on the Business Combination and will contain important information about the Business Combination and related matters. Shareholders of ROSS and other interested persons are advised to read, when available, these materials (including any amendments or supplements thereto) and any other relevant documents, because they will contain important information about ROSS, PubCo, APRINOIA and the Business Combination. Shareholders and other interested persons will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, and other relevant materials in connection with the Business Combination, without charge, once available, at the SEC’s website at www.sec.gov or by directing a request to: Ross Acquisition Corp II, 1 Pelican Lane, Palm Beach, Florida 33480, Attn: Wilbur L. Ross Jr., Chief Executive Officer. The information contained on, or that may be accessed through, the websites referenced in this communication in each case is not incorporated by reference into, and is not a part of, this communication.
BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF ROSS ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH THE BUSINESS COMBINATION AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION.
Participants in the Solicitation
ROSS, PubCo, APRINOIA and their respective directors and executive officers may be deemed participants in the solicitation of proxies from ROSS’s shareholders in connection with the Business Combination. ROSS’s shareholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of ROSS in ROSS’s Form 10-K, filed with the SEC on March 31, 2022, or its most recent Form 10-Q, filed with the SEC on November 14, 2022. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to ROSS’s shareholders in connection with the Business Combination will be set forth in the proxy statement/prospectus for the Business Combination, accompanying the Registration Statement that PubCo and ROSS intend to file with the SEC. Additional information regarding the interests of participants in the solicitation of proxies in connection with the Business Combination will likewise be included in that Registration Statement. You may obtain free copies of these documents as described above.
No Offer or Solicitation
This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Business Combination and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended, or an exemption therefrom.
Cautionary Note Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ROSS’s, PubCo’s and/or APRINOIA’s actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. No representations or warranties, express or implied are given in, or in respect of, this communication. When we use words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.
These forward-looking statements and factors that may cause actual results to differ materially from current expectations include, but are not limited to: the ability of the parties to complete the Business Combination and other transactions contemplated by the Business Combination Agreement in a timely manner or at all; the risk that the Business Combination or other business combination may not be completed by ROSS’s business combination deadline and the potential failure to obtain an extension of the business combination deadline; the outcome of any legal proceedings or government or regulatory action on inquiry that may be instituted against ROSS, PubCo, APRINOIA or others following the announcement of the Business Combination and any definitive agreements with respect thereto; the inability to satisfy the conditions to the consummation of the Business Combination, including the approval of the Business Combination by the shareholders of ROSS and APRINOIA; the occurrence of any event, change or other circumstance that could give rise to the termination of the Business Combination Agreement relating to the Business Combination; the ability to meet stock exchange listing standards following the consummation of the Business Combination; the effect of the announcement or pendency of the Business Combination on APRINOIA’s business relationships, operating results, current plans and operations of PubCo and APRINOIA; the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of PubCo to grow and manage growth profitably; the possibility that ROSS, PubCo and/or APRINOIA may be adversely affected by other economic, business, and/or competitive factors; estimates by ROSS, PubCo or APRINOIA of expenses and profitability; expectations with respect to future operating and financial performance and growth, including the timing of the completion of the Business Combination; plans, intentions or future operations of PubCo or APRINOIA, including relating to the finalization, completion of any studies, feasibility studies or other assessments or relating to attainment, retention or renewal of any assessments, permits, licenses or other governmental notices or approvals, or the commencement or continuation of any construction or operations of plants or facilities; APRINOIA’s and PubCo’s ability to execute on their business plans and strategy; and other risks and uncertainties described from time to time in filings with the SEC.
The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Registration Statement referenced above and other documents filed by ROSS and PubCo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. There may be additional risks that neither ROSS, PubCo nor APRINOIA presently know, or that ROSS, PubCo, and/or APRINOIA currently believe are immaterial, that could cause actual results to differ from those contained in the forward-looking statements. For these reasons, among others, investors and other interested persons are cautioned not to place undue reliance upon any forward-looking statements in this communication. None of ROSS, PubCo or APRINOIA undertakes any obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this communication, except as required by applicable law.
APRINOIA Investor Relations
Matt Hughes
mhughes@allelecommunications.com
APRINOIA Media Contact
Jessica Starman
jessica@elev8newmedia.com
ROSS Investor Relations and Media Contact
Wilbur Ross
917-414-5318
wilburross@icloud.com
ROSS SPACは、APRINOIA Therapeuticsのために2億8000万ドルの株式を発行します。
APRINOIA Therapeuticsは、中枢神経系に特化した診断薬および中枢神経系タンパク分解剤を含む治療薬の開発に注力する精密神経科企業であり、本買収により、データ発表までのいくつかの主要な治療・診断プログラムの資金調達が見込まれる。
本経営統合は、2023年上半期に完了する予定であり、統合会社はクロージング時にナスダックまたはニューヨーク証券取引所での上場を予定しています。
フロリダ州パームビーチおよびマサチューセッツ州ケンブリッジ、2023年1月18日 – アルツハイマー病（以下「AD」）や進行性核上性麻痺（以下「PSP」）などの神経変性疾患に焦点を当てた臨床段階のバイオテクノロジー企業、APRINOIA Therapeutics Inc（以下、「APRINOIA」）と、Ross Acquisition Corp II (NYSE: ROSS, ROSS. U, ROSS WS) は、本日、前商務長官Wilbur Rossが設立した特別目的買収会社であるRossと、正式契約（以下「経営統合契約」）を締結しましたのでお知らせします。 U, ROSS WS）（以下「ROSS」）は、本日、Wilbur Ross前商務長官が設立した特別目的買収会社であるROSSと、企業結合（以下「本企業結合」）に関する最終契約（以下「本企業結合契約」）を締結したことをお知らせします。
ROSSとAPRINOIAは、APRINOIAの完全希薄化後取引株式価値として280百万米ドルで統合されます。 本経営統合の一環として、ロス氏は個人的に750万米ドルの転換社債を発行し、本経営統合のクロージング（以下、クロージング）時に最大1250万米ドルの資本注入を行うことを確約しています。 この資金は、当社の主力製品である18F-APN-1607（以下「APN-1607」）を中国において商業化するために必要な資金を充当することを目的としています。
2015年に法人化されたAPRINOIAは、マサチューセッツ州ケンブリッジに拠点を置くグローバル臨床段階のバイオテクノロジー企業で、バイオジェンやセルジーン（ブリストル・マイヤーズスクイブが買収）といった世界有数のバイオテクノロジー企業と共同で神経変性疾患の治療に向けた新規治療薬や精密診断薬の開発を行っており、その中にはリードタウPETトレーサー「APN-1607」に関する一定の非独占的ライセンス契約も含まれています。この発表と同時に、APRINOIA は APN-1607 の中国における権利を大手製薬会社に導出したことを発表しました。この契約により、ライセンシーは本製品を AD に対する現在のフェーズ 3 試験に進め、2024 年までに中国での APN-1607 を商業化することに同意し、規制当局の審査と承認を受けることとなりました。ライセンシーは、契約一時金として約8百万米ドルおよび14百万人民元を約束し、約1千万人のAD患者がいると推定される中国において、マイルストーン支払いおよび売上の最大15%のロイヤルティを約束します。APRINOIAは、他の管轄区域におけるAPN-1607の開発を引き続き主導していきます。APN-1607は、米国、日本、台湾でADの第2相試験を実施中であり、米国ではFDAの規制当局の承認を前提に、PSPの第3相試験の準備を進めています。
APRINOIAは、独自のPET診断用トレーサー、低分子モジュレーター、抗体、分解剤という異なるモダリティを持つ4つのプラットフォームを確立しています。各モードは、ADやパーキンソン病などの一般的な疾患だけでなく、PSP、多系統萎縮症（MSA）、前頭側頭型認知症（FTD）などの稀な認知症や運動障害の病因となるタウ、α-シヌクレイン、TDP43などの病的凝集蛋白をターゲットとしています。
APN-1607は、旧世代トレーサーよりも病的なタウ凝集体に対する特異性が高く、オフターゲットプロファイルが改善された新世代のタウPETトレーサーである。APN-1607は、2,600人以上の被験者で検証され、PSP、大脳皮質変性症（CBD）、外傷性脳損傷などのADおよび非ADタウパチーにおけるタウタンパク質の異常量と空間分布を差次的に定量化できる幅広い臨床有用性が実証されています。その結果、より早い段階での正確な臨床診断、疾患の異なるステージの区別、経時的な疾患進行のモニタリング、異なるタイプの神経変性疾患の鑑別を可能にすることが期待されます。APRINOIAは、ADやPSPなどの疾患において、画像検証された結合剤が疾患の悪化と統計的に有意な相関を示すという利点（医師のスコアリングに基づく）を生かして、タンパク質分解剤の中核を形成しています。APRINOIAの目標は、単独または製薬会社と共同で、CNSタンパク質分解分子をヒト臨床試験に進める最初の企業になることです。
APN-1607は、旧世代よりも病的なタウ凝集体に対する特異性が高く、オフターゲットプロファイルが改善された新世代のタウPETトレーサーである。APN-1607は、2,600人以上の被験者で検証され、PSP、大脳皮質変性症（CBD）、外傷性脳損傷などのADおよび非ADタウパチーにおけるタウタンパク質の異常量と空間分布を差次的に定量化できる幅広い臨床有用性が実証されています。その結果、より早い段階での正確な臨床診断、疾患の異なるステージの区別、経時的な疾患進行のモニタリング、異なるタイプの神経変性疾患の鑑別を可能にすることが期待されます。APRINOIAは、ADやPSPなどの疾患において、画像検証された結合剤が疾患の悪化と統計的に有意な相関を示すという利点（医師のスコアリングに基づく）を生かして、タンパク質分解剤の中核を形成しています。APRINOIAの目標は、単独または製薬会社と共同で、CNSタンパク質分解分子をヒト臨床試験に進める最初の企業になることです。
また、APRINOIA社は、現在、タウ抗体APN-005のフェーズ1試験を米国で実施しています。この抗体は、タウのミッドドメイン領域にあるコンフォメーション依存性のエピトープを標的としており、このエピトープは凝集型タウにのみ存在すると考えられています。
“精密な神経科学の実現に向け、神経変性に関する献身的な研究開発を7年間続けてきた当社は、金融と企業発展の次の段階へ進むことができ、大変嬉しく思っています。当社の研究開発と共同研究の成功は、当社の製品、チーム、そして研究・商業パートナーのサポートの質の高さを示すものです。当社は今後も会社とパイプラインを成長させ、重要な医療ニーズを持つ医師や患者さんのために革新的な製品を開発していきます」と、APRINOIAのCEOであるMing-Kuei Jangは述べています。
「当社は、APRINOIA社と提携し、最も重要な疾患領域の1つであるアルツハイマー病への取り組みを支援できることを嬉しく思っています。現在、米国では650万人以上のアルツハイマー病患者がおり、その経済的負担は2040年までに3500億米ドル以上に達すると予想されていることから、この問題は私たちが注目すべきものであることが明らかになりました。APRINOIAのタウアプローチは、レカネマブのようなベータアミロイドベースの製品を補完する可能性を持っています。我々は、過去2年間におけるこの分野での進展に勇気づけられ、この分野の発展を継続するために適切な時期にAPRINOIA社と提携できたと信じています」とROSSのCEOであるWilbur Rossは、述べています。
ROSSのM&A責任者であるNadim Qureshiは、「APRINOIA社は、世界的に増加し続けている神経変性疾患であるタウ疾患とαシヌクレイン疾患に焦点を当てた先端バイオテクノロジー企業です」と付け加えました。
本経営統合の概要
ROSSは、APRINOIAとの間で、APRINOIAとROSSが、新たに設立される統合会社APRINOIA Therapeutics Holdings Limited（以下「PubCo」）の100％子会社となることを内容とする経営統合契約を締結しました。本経営統合により、買収完了後の統合会社の企業価値は、最大で319.6百万米ドルとなります。
本経営統合の一環として、アプリノイアの既存株主は全員、保有するアプリノイア株式の100％をPubCoに転籍する予定です。APRINOIAの既存株主は、ROSSの株主による償還の程度に応じて、PubCoの42％から74％の株式を保有することになる見込みです。
APRINOIAは、ROSSの株主による償還後、ROSSの信託口座に保管されている残りの資金、ウィルバー・ロス氏の関連会社から750万米ドル、APRINOIAの既存株主を含むその他の投資家から500万米ドルのコミットメントを受け取る予定です。現在、ROSSの信託口座には約3億5,060万米ドルが保有されています。
本経営統合は、ROSSの株主による承認を含む慣習的な承認と条件に従い、本年前半にクロージングする予定であり、ROSSとアプリノイアの取締役会は、それぞれ全会一致で承認しています。クロージング後、APRINOIAの事業はAPRINOIAの社名で運営される予定です。企業結合契約の条項に従い、クロージングの条件として、PubCoは、本企業結合に関連して発行されるPubCo普通株式のNYSEまたはNasdaqへの上場を承認させる必要がありますが、かかる上場条件が満たされることを保証するものではありません。
投資家向けプレゼンテーション
APRINOIAとRoss Acquisition Corp IIは、2023年1月18日（水）午後4時30分（米国東部時間）に投資家向け電話会議とスライドプレゼンテーションを開催します。ウェブキャストとダイヤルイン情報は以下の通りです。
https://event.choruscall.com/mediaframe/webcast.html?webcastid=GOhNT3ve
コンファレンスコール： 877-407-8029 または +1 201 689-8029
本経営統合に関する詳細な情報を記載した投資家向けプレゼンテーションは、Form 8-KによるCurrent Reportの添付資料としてROSSにより提出され、米国証券取引委員会（以下「SEC」）のウェブサイト（www.sec.gov）で閲覧することができます。
アドバイザー
BTIG, LLCは、本経営統合に係るAPRINOIAの財務アドバイザーを務めました。Allele Capital Partners, LLCは、APRINOIAの戦略アドバイザーを務めました。
Cooley LLPは、本経営統合に関し、APRINOIAの法務アドバイザーを務めました。
White & Case LLPは、本経営統合に関し、ROSSのリーガル・アドバイザーを務めました。Jones Dayは、証券取引に関する事項について、ROSSの法律顧問を務めました。
APRINOIAについて
2015年に法人化されたAPRINOIA Therapeutics Inc.は、マサチューセッツ州ケンブリッジに拠点を置くグローバルな臨床段階のバイオテクノロジー企業で、世界の主要バイオテクノロジー企業と共同で神経変性疾患の治療のための新規治療薬および精密診断薬の開発を行っています。
ロス・アクイジション・コーポレーションIIについて
Ross Acquisition Corp II は、Wilbur L. Ross、Stephen J. Toy、Nadim Z. Qureshi の関連会社である Ross Holding Company LLC が出資する特別目的買収会社で、1つ以上の企業や資産との合併、資本交換、資産買収、株式購入、組織再編、または同様の企業結合を目的としています。Qureshiの関連会社であるRoss Holding Company LLCが主催する特別目的買収会社で、1つ以上の事業または資産との合併、資本交換、資産買収、株式購入、組織再編または類似の企業結合を目的としています。Ross Acquisition Corp IIは、2021年3月に新規株式公開を完了し、約3億4,500万ドルの現金収入を得ました。